The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Studying the effects of NOD2 aberrations in lung cancer
Megan Babette Barnet, MD, The Kinghorn Cancer Centre, Darlinghurst, Australia, describes the results of a three-part study. The initial index case involved a patient with melanoma who had a complete abscopal response concurrent with a flair of Crohn’s colitis, which is associated with NOD2 defects. Whole genome sequencing unveiled both alleles were dysfunctional for NOD2. These findings allowed for the use of a MC38 inoculated mouse model, where tumors were found to respond better to PD1 treatment. Flow cytometry analysis showed differences between frameshift and wild-type tumors, where there more effector cells within the tumors, thus replicating the clinical benefit seen. The final part of the study involved running whole genome sequencing on prospectively recruited patients with lung cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
